Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03664804 · ClinicalTrials.gov registry record · Phase 1
Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 95
- Enrollment target
NCT03664804 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 95 participants.
The verdict
NCT03664804, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 95 participants
- Enrollment target
Study Summary
The study is designed as a multi-site, prospective, 15-month longitudinal, cohort study measuring CSF mHTT in participants with early manifest Stage I or Stage II Huntington's Disease (HD).
Interventions
- OTHER No Study Drug was Administered in this Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2018-12-05 |
| Est. Completion | 2022-05-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03664804
The ClinicalTrials.gov registry entry for NCT03664804 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No Study Drug was Administered in this Study is the first listed.
NCT03664804 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03664804 about?
NCT03664804 is a clinical study titled "Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease". The study is designed as a multi-site, prospective, 15-month longitudinal, cohort study measuring CSF mHTT in participants with early manifest Stage I or Stage II Huntington's Disease (HD).
What is the current status of trial NCT03664804?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2018-12-05. Estimated completion is 2022-05-07.
What interventions are being tested in trial NCT03664804?
The interventions under investigation include: No Study Drug was Administered in this Study (OTHER).
Who is sponsoring clinical trial NCT03664804?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.